{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T13:16:47Z","timestamp":1786195007416,"version":"build-2736575974"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","translationalres.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.trsl.2018.10.003","type":"journal-article","created":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T03:36:36Z","timestamp":1539315396000},"page":"77-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"special_numbering":"C","title":["Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes"],"prefix":"10.1016","volume":"205","author":[{"given":"Lydia","family":"Giannopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Zavridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Kasimir-Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7796-5914","authenticated-orcid":false,"given":"Evi S.","family":"Lianidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2018.10.003_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.trsl.2018.10.003_bib0002","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2018.10.003_bib0003","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1016\/j.trsl.2018.10.003_bib0004","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1525-1438.2005.15356.x","article-title":"Future options for first-line therapy of advanced ovarian cancer","volume":"15","author":"Du Bois","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.trsl.2018.10.003_bib0005","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2018.10.003_bib0006","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0007","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2014.05.002","article-title":"Hematogenous metastasis of ovarian cancer: rethinking mode of spread","volume":"26","author":"Pradeep","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trsl.2018.10.003_bib0008","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1152\/ajpcell.00188.2015","article-title":"Cellular and molecular processes in ovarian cancer metastasis. a review in the theme: cell and molecular processes in cancer metastasis","volume":"309","author":"Yeung","year":"2015","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.trsl.2018.10.003_bib0010","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.trsl.2018.10.003_bib0011","series-title":"Tietz Textbook of Clinical Chemistry and Molecular Diagnostics","first-page":"1111","article-title":"Circulating Tumor Cells and circulating Tumor DNA","author":"Lianidou","year":"2017"},{"key":"10.1016\/j.trsl.2018.10.003_bib0012","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","article-title":"Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy","volume":"6","author":"Alix-Panabieres","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.trsl.2018.10.003_bib0013","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000478253","article-title":"Exosomes: a cancer theranostics road map","volume":"20","author":"Panagiotara","year":"2017","journal-title":"Public Health Genomics"},{"key":"10.1016\/j.trsl.2018.10.003_bib0014","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrclinonc.2014.5","article-title":"Clinical relevance of circulating cell-free microRNAs in cancer","volume":"11","author":"Schwarzenbach","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0015","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1159\/000478018","article-title":"Liquid biopsy: current status and future perspectives","volume":"40","author":"Mader","year":"2017","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.trsl.2018.10.003_bib0016","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13048-017-0369-5","article-title":"Circulating cell-free DNA and circulating tumor cells, the \u201cliquid biopsies\u201d in ovarian cancer","volume":"10","author":"Cheng","year":"2017","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.trsl.2018.10.003_bib0017","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s13277-015-4299-9","article-title":"Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer","volume":"37","author":"Gasparri","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0018","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1515\/cclm-2017-0019","article-title":"Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA","volume":"56","author":"Giannopoulou","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.trsl.2018.10.003_bib0019","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ygyno.2014.03.016","article-title":"Circulating and disseminated tumor cells in ovarian cancer: a systematic review","volume":"133","author":"Romero-Laorden","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0020","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.ejso.2016.05.010","article-title":"Current and future role of circulating tumor cells in patients with epithelial ovarian cancer","volume":"42","author":"Van Berckelaer","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0021","article-title":"Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis","volume":"11","author":"Zhou","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2018.10.003_bib0022","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41571-018-0035-x","article-title":"Clinical utility of circulating non-coding RNAs - an update","volume":"15","author":"Anfossi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0023","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1098\/rstb.2016.0486","article-title":"MicroRNAs and miRceptors: a new mechanism of action for intercellular communication","volume":"373","author":"Fabbri","year":"2018","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.trsl.2018.10.003_bib0024","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1172\/JCI81135","article-title":"The biology and function of exosomes in cancer","volume":"126","author":"Kalluri","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2018.10.003_bib0025","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1373\/clinchem.2017.283531","article-title":"RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast Cancer Patients","volume":"64","author":"Keup","year":"2018","journal-title":"Clin Chem"},{"key":"10.1016\/j.trsl.2018.10.003_bib0026","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-017-0659-y","article-title":"The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer","volume":"16","author":"Li","year":"2017","journal-title":"Mol Cancer"},{"key":"10.1016\/j.trsl.2018.10.003_bib0027","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2016.03.036","article-title":"The biological significance and clinical applications of exosomes in ovarian cancer","volume":"142","author":"Dorayappan","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0028","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1586\/14789450.2016.1165613","article-title":"Extracellular vesicles in ovarian cancer: applications to tumor biology, immunotherapy and biomarker discovery","volume":"13","author":"Nawaz","year":"2016","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.trsl.2018.10.003_bib0029","first-page":"3363","article-title":"The added value of circulating tumor cells examination in ovarian cancer staging","volume":"5","author":"Kolostova","year":"2015","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.trsl.2018.10.003_bib0030","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ygyno.2017.02.042","article-title":"Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer","volume":"145","author":"Lee","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0031","doi-asserted-by":"crossref","first-page":"812","DOI":"10.18632\/oncotarget.22549","article-title":"Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells","volume":"9","author":"Obermayr","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.trsl.2018.10.003_bib0032","doi-asserted-by":"crossref","first-page":"48820","DOI":"10.18632\/oncotarget.16179","article-title":"EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy","volume":"8","author":"Chebouti","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.trsl.2018.10.003_bib0033","doi-asserted-by":"crossref","first-page":"106415","DOI":"10.18632\/oncotarget.22468","article-title":"Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? A study of the OVCAD consortium","volume":"8","author":"Obermayr","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.trsl.2018.10.003_bib0034","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ygyno.2018.02.020","article-title":"Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium","volume":"149","author":"Gostner","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2012.09.021","article-title":"Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance \u2013 a study of the OVCAD consortium","volume":"128","author":"Obermayr","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0036","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.18632\/oncotarget.23943","article-title":"Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer","volume":"9","author":"Guo","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.trsl.2018.10.003_bib0037","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2015.03.002","article-title":"Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs)","volume":"137","author":"Pearl","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0038","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0039","article-title":"Clinical value of ALU concentration and integrity index for the early diagnosis of ovarian cancer: a retrospective cohort trial","volume":"13","author":"Zhang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2018.10.003_bib0040","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13073-017-0500-7","article-title":"The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer","volume":"9","author":"Widschwendter","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.trsl.2018.10.003_bib0041","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ygyno.2018.05.026","article-title":"ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer","volume":"150","author":"Giannopoulou","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0042","doi-asserted-by":"crossref","first-page":"328","DOI":"10.5468\/ogs.2018.61.3.328","article-title":"Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer","volume":"61","author":"Park","year":"2018","journal-title":"Obstet Gynecol Sci"},{"key":"10.1016\/j.trsl.2018.10.003_bib0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002198","article-title":"Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study","volume":"13","author":"Parkinson","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.trsl.2018.10.003_bib0044","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.2016.70.4627","article-title":"Reversion of BRCA1\/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer","volume":"35","author":"Christie","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0045","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","article-title":"Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer","volume":"23","author":"Weigelt","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2018.10.003_bib0046","doi-asserted-by":"crossref","first-page":"101325","DOI":"10.18632\/oncotarget.20722","article-title":"Detection of BRCA1\/2 mutations in circulating tumor DNA from patients with ovarian cancer","volume":"8","author":"Ratajska","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.trsl.2018.10.003_bib0047","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1541-7786.MCR-17-0594","article-title":"Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma","volume":"16","author":"Arend","year":"2018","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.trsl.2018.10.003_bib0048","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/mgg3.414","article-title":"Next-generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug-resistant recurrent ovarian cancer","volume":"6","author":"Du","year":"2018","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.trsl.2018.10.003_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aan2415","article-title":"Direct detection of early-stage cancers using circulating tumor DNA","volume":"9","author":"Phallen","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2018.10.003_bib0050","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-016-0536-0","article-title":"Clinical relevance of circulating cell-free microRNAs in ovarian cancer","volume":"15","author":"Nakamura","year":"2016","journal-title":"Mol Cancer"},{"key":"10.1016\/j.trsl.2018.10.003_bib0051","first-page":"123","article-title":"Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer","volume":"10","author":"Zheng","year":"2013","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.trsl.2018.10.003_bib0052","first-page":"1","article-title":"Identification of circulating microRNAs as diagnostic biomarkers for ovarian cancer: a pooled analysis of individual studies","author":"Zhou","year":"2018","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.trsl.2018.10.003_bib0053","doi-asserted-by":"crossref","first-page":"66620","DOI":"10.18632\/oncotarget.18129","article-title":"Comprehensive analysis on diagnostic value of circulating miRNAs for patients with ovarian cancer","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.trsl.2018.10.003_bib0054","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1373\/clinchem.2013.213066","article-title":"Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer","volume":"60","author":"Kuhlmann","year":"2014","journal-title":"Clin Chem"},{"key":"10.1016\/j.trsl.2018.10.003_bib0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ygyno.2008.08.036","article-title":"The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform","volume":"112","author":"Resnick","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0056","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.bjc.6605833","article-title":"Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening","volume":"103","author":"Hausler","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.trsl.2018.10.003_bib0057","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1186\/1471-2407-12-627","article-title":"Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer","volume":"12","author":"Kan","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.trsl.2018.10.003_bib0058","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s12094-015-1303-1","article-title":"Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features","volume":"17","author":"Zuberi","year":"2015","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0059","doi-asserted-by":"crossref","first-page":"36815","DOI":"10.18632\/oncotarget.5766","article-title":"Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre\/post-treatment variation compared to CA-125 and potential for prediction of progression-free survival","volume":"6","author":"Kapetanakis","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.trsl.2018.10.003_bib0060","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/0300060513475759","article-title":"Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer","volume":"41","author":"Hong","year":"2013","journal-title":"J Int Med Res"},{"key":"10.1016\/j.trsl.2018.10.003_bib0061","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1177\/0300060513487652","article-title":"Serum microRNA-92 expression in patients with ovarian epithelial carcinoma","volume":"41","author":"Guo","year":"2013","journal-title":"J Int Med Res"},{"key":"10.1016\/j.trsl.2018.10.003_bib0062","first-page":"33","article-title":"Serum MicroRNA-21 negatively relates to expression of programmed cell death-4 in patients with epithelial ovarian cancer","volume":"19","author":"Mahmoud","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.trsl.2018.10.003_bib0063","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.7314\/APJCP.2013.14.2.1057","article-title":"Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer","volume":"14","author":"Xu","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.trsl.2018.10.003_bib0064","doi-asserted-by":"crossref","first-page":"e86871","DOI":"10.1371\/journal.pone.0086871","article-title":"MiR-26a promotes ovarian cancer proliferation and tumorigenesis","volume":"9","author":"Shen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2018.10.003_bib0065","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.bbrc.2013.10.053","article-title":"MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1","volume":"441","author":"Wu","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.trsl.2018.10.003_bib0066","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1007\/s13277-015-3191-y","article-title":"Serum microRNA-145 as a novel biomarker in human ovarian cancer","volume":"36","author":"Liang","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0067","doi-asserted-by":"crossref","first-page":"e77853","DOI":"10.1371\/journal.pone.0077853","article-title":"Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer","volume":"8","author":"Zheng","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2018.10.003_bib0068","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1158\/1078-0432.CCR-12-2726","article-title":"Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer","volume":"19","author":"Suryawanshi","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2018.10.003_bib0069","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.biopha.2013.12.001","article-title":"miR-99a promotes proliferation targeting FGFR3 in human epithelial ovarian cancer cells","volume":"68","author":"Jiang","year":"2014","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.trsl.2018.10.003_bib0070","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3109\/01443615.2014.919998","article-title":"Circulating microRNA expression profiles in ovarian cancer","volume":"34","author":"Ayaz","year":"2014","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0071","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.canlet.2014.10.010","article-title":"A novel serum microRNA panel to discriminate benign from malignant ovarian disease","volume":"356","author":"Langhe","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.trsl.2018.10.003_bib0072","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/bjc.2013.795","article-title":"Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes","volume":"110","author":"Shapira","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.trsl.2018.10.003_bib0073","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.7314\/APJCP.2014.15.4.1739","article-title":"Differential microRNA expression by Solexa sequencing in the sera of ovarian cancer patients","volume":"15","author":"Ji","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.trsl.2018.10.003_bib0074","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1007\/s13277-015-3138-3","article-title":"MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer","volume":"36","author":"Gao","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0075","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/bjc.2015.340","article-title":"Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients","volume":"113","author":"Meng","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.trsl.2018.10.003_bib0076","doi-asserted-by":"crossref","first-page":"11259","DOI":"10.1007\/s13277-016-4993-2","article-title":"The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer","volume":"37","author":"Zuberi","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0077","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153902","article-title":"Utility of serum miR-125b as a diagnostic and prognostic indicator and its alliance with a panel of tumor suppressor genes in epithelial ovarian cancer","volume":"11","author":"Zuberi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2018.10.003_bib0078","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/IGC.0000000000000846","article-title":"A pilot study of circulating microRNA-125b as a diagnostic and prognostic biomarker for epithelial ovarian cancer","volume":"27","author":"Zhu","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.trsl.2018.10.003_bib0079","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-42044-8_1","article-title":"Circulating cell-free miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer","volume":"924","author":"Meng","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.biopha.2016.05.049","article-title":"Decreased expression of microRNA-148a predicts poor prognosis in ovarian cancer and associates with tumor growth and metastasis","volume":"83","author":"Gong","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.trsl.2018.10.003_bib0081","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lfs.2016.12.007","article-title":"MiR-376a promotion of proliferation and metastases in ovarian cancer: potential role as a biomarker","volume":"173","author":"Yang","year":"2017","journal-title":"Life Sci"},{"key":"10.1016\/j.trsl.2018.10.003_bib0082","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.canlet.2016.12.017","article-title":"Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: a validation across two independent cohorts","volume":"388","author":"Todeschini","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.trsl.2018.10.003_bib0083","doi-asserted-by":"crossref","first-page":"89811","DOI":"10.18632\/oncotarget.20688","article-title":"A combination of circulating miRNAs for the early detection of ovarian cancer","volume":"8","author":"Yokoi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.trsl.2018.10.003_bib0084","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejogrb.2018.01.006","article-title":"Serum miR-1181 and miR-4314 associated with ovarian cancer: MiRNA microarray data analysis for a pilot study","volume":"222","author":"Ruan","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0085","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s12253-018-0392-x","article-title":"Diagnostic model of serum miR-193a-5p, HE4 and CA125 improves the diagnostic efficacy of epithelium ovarian cancer","volume":"24","author":"ren","year":"2018","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.trsl.2018.10.003_bib0086","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.28932","article-title":"Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer","volume":"6","author":"Elias","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.trsl.2018.10.003_bib0087","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2017.11.005","article-title":"Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer","volume":"148","author":"Shah","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0088","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tjog.2014.07.005","article-title":"Serum microRNAs in clear cell carcinoma of the ovary","volume":"53","author":"Chao","year":"2014","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0089","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/cas.13210","article-title":"MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer","volume":"108","author":"Fukagawa","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1016\/j.trsl.2018.10.003_bib0090","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/0008-5472.CAN-17-3014","article-title":"miRNA-590-3p promotes ovarian cancer growth and metastasis via a novel FOXA2-versican pathway","volume":"78","author":"Salem","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2018.10.003_bib0091","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141279","article-title":"Carboplatin with decitabine therapy, in recurrent platinum resistant ovarian cancer, alters circulating mirnas concentrations: a pilot study","volume":"10","author":"Benson","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2018.10.003_bib0092","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3098542","article-title":"Evaluation of prognostic and predictive significance of circulating micrornas in ovarian cancer patients","volume":"2017","author":"Halvorsen","year":"2017","journal-title":"Dis Markers"},{"key":"10.1016\/j.trsl.2018.10.003_bib0093","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ygyno.2008.04.033","article-title":"MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer","volume":"110","author":"Taylor","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0094","doi-asserted-by":"crossref","first-page":"16923","DOI":"10.18632\/oncotarget.7850","article-title":"Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer","volume":"7","author":"Meng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.trsl.2018.10.003_bib0095","doi-asserted-by":"crossref","first-page":"43076","DOI":"10.18632\/oncotarget.9246","article-title":"Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages","volume":"7","author":"Ying","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.trsl.2018.10.003_bib0096","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/2211-5463.12257","article-title":"MiR-101 inhibits ovarian carcinogenesis by repressing the expression of brain-derived neurotrophic factor","volume":"7","author":"Xu","year":"2017","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.trsl.2018.10.003_bib0097","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-94-017-7215-0_14","article-title":"The role of CA 125 as tumor marker: biochemical and clinical aspects","volume":"867","author":"Bottoni","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.trsl.2018.10.003_bib0098","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/B978-0-12-801401-1.00002-5","article-title":"Ovarian cancer biomarkers: current state and future implications from high-throughput technologies","volume":"66","author":"Leung","year":"2014","journal-title":"Adv Clin Chem"},{"key":"10.1016\/j.trsl.2018.10.003_bib0099","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1158\/1078-0432.CCR-14-1190","article-title":"Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility","volume":"21","author":"Ignatiadis","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524418301865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524418301865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T22:22:04Z","timestamp":1605219724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524418301865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":99,"alternative-id":["S1931524418301865"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2018.10.003","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2018.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}